Literature DB >> 23381979

Mucor infection: difficult diagnosis.

Margarida Badior1, Fernanda Trigo, Catarina Eloy, José Eduardo Guimarães.   

Abstract

Mucormycosis is a rare, highly aggressive and usually fatal infection, which affects immunocompromised patients. This case report describes a patient with acute promyelocytic leukemia who received antifungal therapy for a suspected pulmonary Aspergillus infection. Material from a lobectomy suggested that on histologic grounds the diagnosis had to be changed to mucormycosis. High suspicion of a Mucor infection favors early detection and timely appropriate antifungal therapy, which is crucial for the prognosis of these patients.

Entities:  

Mesh:

Year:  2013        PMID: 23381979     DOI: 10.1007/s40261-012-0014-4

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  6 in total

1.  Mucormycosis in hematologic malignancies: an emerging fungal infection.

Authors:  A Nosari; P Oreste; M Montillo; G Carrafiello; M Draisci; G Muti; A Molteni; E Morra
Journal:  Haematologica       Date:  2000-10       Impact factor: 9.941

2.  Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.

Authors:  Oliver A Cornely; Angelika Böhme; Dieter Buchheidt; Hermann Einsele; Werner J Heinz; Meinolf Karthaus; Stefan W Krause; William Krüger; Georg Maschmeyer; Olaf Penack; Jörg Ritter; Markus Ruhnke; Michael Sandherr; Michal Sieniawski; Jörg-Janne Vehreschild; Hans-Heinrich Wolf; Andrew J Ullmann
Journal:  Haematologica       Date:  2008-12-09       Impact factor: 9.941

Review 3.  Lipid formulations of amphotericin B as first-line treatment of zygomycosis.

Authors:  G L Petrikkos
Journal:  Clin Microbiol Infect       Date:  2009-10       Impact factor: 8.067

4.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

Review 5.  Fungal infections in leukemia patients: how do we prevent and treat them?

Authors:  Konstantinos Leventakos; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

Review 6.  Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies.

Authors:  Oliver A Cornely; Andrew J Ullmann; Meinolf Karthaus
Journal:  Blood       Date:  2002-08-29       Impact factor: 22.113

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.